Combining Immunotherapy with Transarterial Radioembolization

Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy. In this cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Balaban Genc, Zeynep Ceren, Soydemır, Efe, Ersoy, Seval Ay, Ones, Tunc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348490/
https://www.ncbi.nlm.nih.gov/pubmed/37456187
http://dx.doi.org/10.4103/ijnm.ijnm_180_22
Descripción
Sumario:Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy. In this case report, we reported that transarterial radioembolization and immunotherapy such as atezolizumab and bevacizumab can be used together in a manner effectively in the management of HCC treatment.

Ejemplares similares